'''Delucemine''' ('''NPS-1506''') is a drug which acts as an [[NMDA antagonist]] and a [[serotonin reuptake inhibitor]], and has [[neuroprotective]] effects.<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1999.tb08023.x/abstract | title=NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. | vauthors=Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D | journal=Annals of the New York Academy of Sciences | date=December 1999 | volume=890 | pages=450–457 | doi=10.1111/j.1749-6632.1999.tb08023.x | pmid=10668449}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0014488600975137 | title=NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat. | author=Matthew J. Leoni | author2=Xiao-Han Chen | author3=Alan L. Mueller | author4=Jessica Cheney | author5=Tracy K. McIntosh | author6=Douglas H. Smith | journal=Experimental Neurology | date=December 2000 | volume=166 | issue=2 | pages=442–449 | doi=10.1006/exnr.2000.7513 | pmid=11085909}}</ref> It was originally investigated for the treatment of [[stroke]] and in 2004 was studied as a potential [[antidepressant]].<ref>[http://sec.edgar-online.com/2004/05/17/0001193125-04-090111/Section8.asp NPS Pharmaceuticals Inc. NPSP Quarterly Report]</ref><ref>{{cite web | url=https://www.google.com/patents/CA2599721A1 | title=Patent CA 2599721 A1 - Pharmaceutical compositions for the treatment and/or prevention of depression | accessdate=24 June 2015 | author=Robert Pyke, Angelo Ceci}}</ref><ref>{{cite web | url=https://www.google.com/patents/WO2014015047A1 | title=Patent WO 2014015047 A1 - Compositions and methods to treat neurodegenerative diseases | accessdate=24 June 2015 | author=Fumito Ichinose | author2=Eizo Marutani | author3=Kotaro Kida}}</ref>
